-Dow Jones
JP Morgan Maintains Overweight on United Therapeutics, Lowers Price Target to $223
JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and lowers the price target from $230 to $223.
Related Posts
What the Viridian Acquisition and SAP Certification Means for Akerna
Enterprise resource platform (ERP) solutions are used to carry out the core processes needed to run a company — finance, manufacturing, HR, supply chain, services, and procurement, among others. Modern ERPs use advanced technologies, such as machine learning and artificial intelligence to provide efficiency across every aspect of a business.
Fastly Shares Spike Higher; Traders Circulate CDN Planet Link Showing Amazon Is Using Fastly CDN
https://www.cdnplanet.com/traffic-share/?query=https://www.amazon.com/&window=24h
Archaea Energy Announces Expansion Of Commercial Partnership With FortisBC Via New 20-Year Renewable Natural Gas Agreement
Archaea Energy Inc. (“Archaea” or “the Company”) (NYSE:LFG), an industry-leading renewable natural gas (“RNG”) company, announced today that it is expanding its commercial partnership